Publications
Yao X, Matosevic S. Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody. 2024,
Immunology Letters, 268, 106881.
Lupo KB, Yao X, Borde S, Wang J, Torregrosa-Allen S, Elzey BD, Utturkar S, Attalah Lanman N, McIntosh M, Matosevic S. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy. 2024,
Nature Communications, 15, 1909.
Das S, Niemeyer E, Leung AZ, Fritsch T, Matosevic S. Human Natural Killer Cells Cryopreserved without DMSO Sustain Robust Effector Responses, 2024,
Molecular Pharmaceutics, 21(2):651-660.
Lupo KB, Torregrosa-Allen S, Elzey BD, Utturkar S, Attalah Lanman N, Cohen-Gadol AC, Slivova V, McIntosh M,Pollok KE, Matosevic S. TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. 2023,
iScience, 26(12):108353.
Borde S, Matosevic S. Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities. 2023,
Trends in Pharmacological Sciences, S0165-6147(23)00179-7.
Wu X, Matosevic S. Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy. 2022,
Molecular Therapy - Oncolytics, 3(27):224-238.
Chambers AM, Lupo KB, Wang J, Cao J, Jalal S, Torregrosa-Allen S, Elzey B, Pine SR, Jalal S, Utturkar S, Attalah Lanman N, Bernal-Crespo V, Matosevic S. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors. 2022,
eLife, 11:e73699.
Chambers AM, Wang J, Dao T, Lupo KB, Veenhuis P, Ayers MG, Slivova V, Cohen-Gadol A, Matosevic S. Functional expression of CD73 on human natural killer cells. 2022,
Cancer Immunology, Immunotherapy, 71(12):3043-3056.
Mamdani H, Matosevic S, Bilal Khalid A, Durm G, Jalal S. Immunotherapy in Lung Cancer: Current Landscape and Future Directions. 2022,
Frontiers in Immunology, 2022; 13: 823618.
Wang J, Torregrosa-Allen S, Elzey BD, Utturkar S, Atallah Lanman N, Bernal-Crespo V, Behymer MM, Knipp GS, Yun Y, Veronesi MC, Sinn AL, Pollok KE, Brutkiewicz R, Nevel KS, Matosevic S. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. 2021,
Proceedings of the National Academy of Sciences USA, 118 (45):e2107507118
Lupo K,* Moon J,* Chambers A, Matosevic S. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions. 2021,
Cytotherapy, 23(10):939-952.
*equal contribution
Yao X, Matosevic S. Cryopreservation of NK and T cells without DMSO for adoptive cell-based immunotherapy. 2021,
BioDrugs, 35(5):529-545.
Yao X, Matosevic S. Chemokine networks modulating natural killer cell trafficking to solid tumors. 2021,
Cytokine and Growth Factor Reviews, 59:36-45.
Dao T, Utturkar S, Atallah Lanman N, Matosevic S. TIM-3 expression is downregulated on human NK cells in response to cancer targets in synergy with activation. 2020,
Cancers, 12(9):2417.
Lupo K, Matosevic S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. 2020,
Journal of Hematology & Oncology, 13(76).
Wang J, Matosevic S. Functional and metabolic targeting of natural killer cells to solid tumors. 2020,
Cellular Oncology, 43(4):577–600.
Matosevic S. Reprogramming of natural killer cells and their use in immunotherapies of solid tumors. 2020,
Immunotherapy, 12(9):605-608.
Yao X, Jovevski JJ*, Todd MF*, Xu R, Li Y, Wang J, Matosevic S. Nanoparticle-mediated intracellular protection of natural killer cells avoids cryoinjury and retains potent anti-tumor functions. 2020,
Advanced Science, 1902938
*equal contribution
An S, Ziegler KF, Zhang P, Wang Y, Kwok T, Xu F, Bi C, Matosevic S, Yin P, Li T, Huang F. Axial plane single-molecule super-resolution microscopy of whole cells. 2020,
Biomedical Optics Express, 11(1):461-479.
Wang J, Matosevic S. NT5E/CD73 as correlative factor of patient survival and natural killer cell infiltration in glioblastoma. 2019,
Journal of Clinical Medicine, 8(10):1526.
Chambers A, Matosevic S. Immunometabolic dysfunction of natural killer cells mediated by the hypoxia-CD73 axis in solid tumors. 2019,
Frontiers in Molecular Biosciences, 6:60.
Lupo K, Matosevic S. Natural killer cells as allogeneic effectors in cancer immunotherapy. 2019,
Cancers, 11(6), 769.
Dao T, Matosevic S. Immunometabolic responses of natural killer cells to inhibitory tumor microenvironment checkpoints. 2019,
Immunometabolism, 2019, 1(1):e190003.
El Assal R, Abou-Elkacem L, Tocchio A, Pasley S, Matosevic S, Kaplan DL, Zylberberg C, Demirci U. Bioinspired preservation of natural killer cells for cancer immunotherapy.
Advanced Science, 2019, 6(6):1802045.
Wang J, Lupo K, Chambers A, Matosevic S. Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. Journal for ImmunoTherapy of Cancer, 2018, 6:136.
Chambers A, Wang J, Lupo K, Yu H, Atallah Lanman N, Matosevic S. Adenosinergic signaling alters natural killer cell functional responses.
Frontiers in Immunology, 2018, 9:2533.
Chambers A*, Lupo K*, Matosevic S. Tumor-microenvironment-induced immunometabolic reprogramming of natural killer cells. Frontiers in Immunology, 2018, 9:2517.
*equal contribution
Matosevic S. Viral and non-viral engineering of natural killer cells as emerging adoptive cancer immunotherapies. Journal of Immunology Research, 2018, Volume 2018, ID 4054815.
Wang J, Matosevic S. Adenosinergic signaling as a target for natural killer cell immunotherapy. Journal of Molecular Medicine, 2018, 96(9):903-913.
*
Cover image
Lin-Gibson S, Hanrahan B, Matosevic S, Schnitzler A, Zhang J, Zylberberg C. Points to Consider for Cell Manufacturing Equipment and Components. Cell & Gene Therapy Insights, 2017, 3(10):793-805.
Pasley S, Zylberberg C, Matosevic S. Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in new DMSO-free media. Immunology Letters, 2017, 192:35-41.
Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Therapy, 2017, 24(8):441-452.
Zylberberg C and Matosevic S. Bioengineered liposome-scaffold composites as therapeutic delivery systems. Therapeutic Delivery, 2017, 8(6):425-445.
Zylberberg C and Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. 2016, Drug Delivery, 23(9):3319-3329.
Knapinska A, Amar S, He Z, Matosevic S, Zylberberg C, Fields G. Matrix metalloproteinases as reagents for cell isolation. Enzyme and Microbial Technology, 2016, 93-94:29-43.
Matosevic S, Paegel BM. Layer-by-layer cell membrane assembly. Nature Chemistry, 2013, 5:958-963.
Matosevic S. State-of-the-art in the development of microfluidic technology toward the synthesis of artificial cells from giant unilamellar vesicles. BioEssays, 2012, 34(11):992-1001.
Matosevic S, Paegel BM. 2011. Stepwise synthesis of giant unilamellar lipid vesicles on a microfluidic assembly line. Journal of the American Chemical Society, 2011, 133(9):2798-2800.
Matosevic S, Lye GJ, Baganz F. Immobilised enzyme microreactor for the quantification of multi-step bioconversions: Characterisation of a de novo transketolase-omega-transaminase pathway to synthesise chiral amino alcohols. Journal of Biotechnology, 2011, 155(3):320-329
Matosevic S, Szita N, Baganz F. Fundamentals and applications of immobilized enzyme microreactors. J Chem Tech Biotech. 86(3):325-334.
Matosevic S, Lye GJ, Baganz F. Development and characterization of a prototype immobilized enzyme microreactor: Quantification of transketolase kinetics. Biotechnology Progress, 2010, 26(1):118-126.
Matosevic S, Micheletti M, Lye GJ, Baganz F. Quantification of kinetics for en-zyme-catalysed reactions: implications for enzyme diffusional limitations at the 10 ml scale. Biotechnology Letters, 2008, 30(6):995-1000.
Venkiteshwaran A, Heider P, Matosevic S, Bogsnes A, Staby A, Sharfstein S, Belfort G. 2007. Optimized Removal of Soluble Host Cell Proteins for the Recovery of met-Human Growth Hormone Inclusion Bodies from Escherichia coli Cell Lysate Using Crossflow Microfiltration. Biotechnology Progress, 23(3):667-672.
